Jefferies Raises Artivion to Strong Buy
Jefferies upgraded Artivion to strong buy. The medical device maker reported quarterly earnings of $0.13 per share and revenue of $125.76 million, topping the revenue estimate. Shares opened at $23.12, and insiders sold about 90,460 shares over the prior 90 days.
Jefferies moved Artivion to a strong-buy rating. Other coverage is mixed: Needham and Canaccord remain positive, Citigroup uses market outperform, Wall Street Zen and Weiss are negative, and MarketBeat’s consensus sits at Moderate Buy with a $42.86 average target.
The medical device maker’s latest quarter showed $0.13 per share and $125.76 million in revenue, above the $119.99 million estimate. The stock opened at $23.12, under both moving averages, while insiders sold about 90,460 shares, valued near $2.56 million, during the prior 90 days.
The upgrade may influence how investors, including retail holders and funds, view Artivion’s near-term prospects, potentially affecting trading and the cost of capital for a medical-device company. Patients and clinicians could be indirectly affected if share-price moves or analyst sentiment shape the company’s investment capacity, though an analyst rating alone does not change product safety, clinical outcomes, or access to care.